News Releases

November 2, 2023
MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to date Emerging evidence of antitumor activity observed in dose cohort three, with one responder noted
May 25, 2023
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combination
Displaying 1 - 10 of 31
* These releases may contain price sensitive information